Poliovirus-binding inhibition ELISA based on specific chicken egg yolk antibodies as an alternative to the neutralization test.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
04 2019
Historique:
received: 26 10 2018
revised: 14 01 2019
accepted: 15 01 2019
pubmed: 21 1 2019
medline: 7 3 2020
entrez: 21 1 2019
Statut: ppublish

Résumé

The first application results of enzyme immunoassay system (ELISA) - binding inhibition ELISA (BI ELISA) for the detection of antibodies to polioviruses of three types based on the use of specific antibodies from chicken yolk (IgY) are presented. This variant of ELISA is a "surrogate" neutralization test (NT). When comparing the results of the detection of antibodies in 90 sera of children who were vaccinated with oral and inactivated poliovirus vaccines, good correlation (r = 0.67, 0.61, 0.76 for types 1, 2, 3 respectively) between the BI ELISA and the NT results was shown. The presented variant of ELISA is the further stage of the development of "IgY-technology" for laboratory diagnostics of viral infections, namely poliovirus infection, which can be used for seroepidemiological studies as an analogue of the NT which requires the use of life poliovirus with the required standard of biosafety containment facilities.

Identifiants

pubmed: 30660606
pii: S0166-0934(18)30531-7
doi: 10.1016/j.jviromet.2019.01.007
pii:
doi:

Substances chimiques

Antibodies, Viral 0
IgY 0
Immunoglobulins 0
Poliovirus Vaccine, Inactivated 0
Poliovirus Vaccine, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-10

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Alexander P Ivanov (AP)

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (FSBSI "Chumakov FSC R&D IBP RAS"), Moscow, 108819, Russia. Electronic address: ivanovalexander1@gmail.com.

Tatiana D Klebleyeva (TD)

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (FSBSI "Chumakov FSC R&D IBP RAS"), Moscow, 108819, Russia.

Lyudmila P Malyshkina (LP)

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (FSBSI "Chumakov FSC R&D IBP RAS"), Moscow, 108819, Russia.

Olga E Ivanova (OE)

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (FSBSI "Chumakov FSC R&D IBP RAS"), Moscow, 108819, Russia; Sechenov First Moscow State Medical University, Moscow, 119991, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH